ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks
ArriVent BioPharma, an early adopter of the China licensing model, reported that its lead lung cancer drug failed a Phase 3 trial. Firmonertinib, an EGFR inhibitor, was first approved for lung ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- ArriVent collapses on disappointing lung cancer data biopharmadive.com